30 November 2020 : Clinical Research
Clinical Outcomes of 130 Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Treated with Palbociclib plus Endocrine Therapy and Subsequent Therapy: A Real-World Single-Center Retrospective Study in China
Chang Liu12CDEF, Ting Li12CDEF, Zhonghua Tao12B, Jun Cao12B, Leiping Wang12B, Jian Zhang12B, Biyun Wang12A, Xichun Hu12A*DOI: 10.12659/MSM.927187
Med Sci Monit 2020; 26:e927187
Table 1 Patient characteristics at palbociclib initiation in different treatment-line settings.
| Characteristic | All patients (n=130) | 1st line (n=42) | ≥2nd line (n=88) | ≥4th line (n=19) |
|---|---|---|---|---|
| Median age, years (range) | 56.0 (31.0–84.0) | 58.0 (35.0–78.0) | 55.0 (31.0–84.0) | 54.0 (32.0–84.0) |
| Menstruation status, n (%) | ||||
| Menopausal | 104 (80.0%) | 33 (78.6%) | 71 (80.7%) | 17 (89.5%) |
| Premenopausal | 26 (20.0%) | 9 (21.4%) | 17 (19.3%) | 2 (10.5%) |
| ECOG PS, n (%) | ||||
| 0 | 1 (0.8%) | 0 (0.0%) | 1 (1.1%) | 0 (0.0%) |
| 1 | 127 (97.7%) | 42 (100.0%) | 85 (96.6%) | 19 (100.0%) |
| 2 | 2 (1.5%) | 0 (0.0%) | 2 (2.3%) | 0 (0.0%) |
| DFS, n (%) | ||||
| ≥1 year | 98 (75.4%) | 23 (54.8%) | 75 (85.2%) | 18 (94.7%) |
| <1 year | 5 (3.8%) | 3 (7.1%) | 2 (2.3%) | 0 (0.0%) |
| MBC | 27 (20.8%) | 16 (38.1%) | 11 (12.5%) | 1 (5.3%) |
| Number of metastatic sites, n (%) | ||||
| <3 | 68 (52.3%) | 26 (61.9%) | 42 (47.7%) | 4 (21.1%) |
| ≥3 | 62 (47.7%) | 16 (38.1%) | 46 (52.3%) | 15 (78.9%) |
| Visceral metastasis, n (%) | ||||
| Yes | 94 (72.3%) | 30 (71.4%) | 64 (72.7%) | 16 (84.2%) |
| No | 36 (27.7%) | 12 (28.6%) | 24 (27.3%) | 3 (15.8%) |
| Prior chemotherapy for MBC | ||||
| Yes | 71 (54.6%) | 11 (26.2%) | 60 (68.2%) | 16 (84.2%) |
| No | 59 (45.4%) | 31 (73.8%) | 28 (31.8%) | 3 (15.8%) |
| Prior lines of ET, n (%) | ||||
| 0 | 42 (32.3%) | 42 (100.0%) | 0 (0.0%) | 0 (0.0%) |
| 1 | 40 (30.8%) | 0 (0.0%) | 40 (45.5%) | 0 (0.0%) |
| 2 | 29 (22.3%) | 0 (0.0%) | 29 (33.0%) | 0 (0.0%) |
| ≥3 | 19 (14.6%) | 0 (0.0%) | 19 (21.5%) | 19 (100.0%) |
| Prior exposure to everolimus, n (%) | ||||
| Yes | 3 (2.3%) | 0 (0.0%) | 3 (3.4%) | 2 (10.5%) |
| No | 127 (97.7%) | 42 (100.0%) | 85 (96.6%) | 17 (89.5%) |
| Sensitivity to ET, n (%) | ||||
| Sensitivity | 25 (19.2%) | 25 (59.5%) | 0 (0.0%) | 0 (0.0%) |
| Acquired resistance | 56 (43.1%) | 11 (26.2%) | 45 (51.1%) | 6 (31.6%) |
| Primary resistance | 49 (37.7%) | 6 (14.3%) | 43 (48.9%) | 13 (68.4%) |
| SD – standard deviation; ECOG PS – Eastern Cooperative Oncology Group Performance status; DFS – disease-free survival; MBC – metastatic breast cancer; ET – endocrine therapy. | ||||